Anktiva plus checkpoint inhibitor therapy demonstrated statistically significant immune restoration across two clinical ...

CheckMate 9LA showed a 26% overall survival benefit for metastatic NSCLC patients treated with nivolumab and ipilimumab plus ...

Despite a significant 48.8% objective response rate and breakthrough therapy status, this regulatory shift reverses years of ...

Newly diagnosed patients with KRAS G12C-mutant advanced or metastatic nonsquamous NSCLC will be enrolled in the trial.

ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced positive results from its ANKTIVA ...

Anktiva, also known as nogapendekin alfa inbakicept, is a new cancer therapy that boosts the immune system to target cancer ...

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the Saudi Food and Drug ...

About 80% of people who have lung cancer have non-small-cell lung cancer. NSCLC usually spreads more slowly than small-cell lung cancers. Both cancers affect the lungs and have similar symptoms, but ...

Explore the latest HER2-targeted therapies for non-small cell lung cancer, including treatment options and patient-centered decision-making strategies.

Researchers headed by a team at Keck Medicine of USC have found that corticosteroids, which are commonly prescribed to non-small cell lung cancer (NSCLC) patients to alleviate cancer-related symptoms, ...

Timing of consolidation durvalumab significantly impacts survival for patients with locally advanced non-small cell lung ...